Oncoliver visualiza el trabajo de los hepatólogos en el manejo del cáncer hepático en España

Red de Centros Oncoliver

Red de centros dedicados al diagnóstico y tratamiento del cáncer de hígado

Mapa de Centros de Referencia Oncoliver

Hospital Universitario Reina Sofía

Responsable U. Cancer: José Luis Montero Álvarez
Persona de contacto: Clara Isabel Linares Luna
Hospital: 957010328
cisabel.linares@imibic.org

>> Ensayos

Hospital Universitario Río Hortega de Valladolid

Responsable U. Cancer: Felix Garcia Pajares
Persona de contacto: Carolina Almohalla Alvarez
Hospital: 983420400. ext 85701
calmohallaalvareza@saludcastillayleon.es

>> Ensayos

Hospital Universitario Vall d’Hebron

Responsable U. Cancer: Beatriz Minguez Rosique
Hospital: 93 274 6140 (ext 6561)
bminguez@vhebron.net

>> Ensayos

Hospital Universitario Infanta Leonor

Responsable U. Cancer: María del Mar Lozano
Persona de contacto: Gemma Carrión Alonso
Hospital: 911918000
cagemma@hotmail.com

>> Ensayos

Hospital Universitario Severo Ochoa

Responsable U. Cancer: María Delgado Galán
Hospital: 914818000
mdelgadogalan@yahoo.es

>> Ensayos

Hospital Insular de Gran Canaria

Responsable U. Cancer: MARIA TERESA FERRER RIOS
Persona de contacto: Paola Saiz Udaeta
Hospital:955012201
paolasaiz@yahoo.es

>> Ensayos

Hospital Universitario Fundación Alcorcón

Responsable U. Cancer: Maria Luisa Gutiérrez García
Hospital:607967681
mlgutierrez@fhalcorcon.es

>> Ensayos

Hospital Universitario Puerta de Hierro

Responsable U. Cancer: José Luis Calleja Panero
Persona de contacto: Rocío Macías
Hospital:911 91 60 00
rociomacias@idiphim.org

>> Ensayos

 

Hospital Virgen del Rocío

Responsable U. Cancer: MARIA TERESA FERRER RIOS
Persona de contacto: Paola Saiz Udaeta
Hospital:955012201
paolasaiz@yahoo.es

>> Ensayos

Hospital General Universitario Alicante

Responsable U. Cancer: SONIA PASCUAL BARTOLOME
Hospital:+34659498209
pascual_son@gva.es

Hospital Virgen de la Concha

Responsable U. Cancer: Pilar Conde Gacho
Hospital: 980548200 (Ext. 48309)
pconde@saludcastillayleon.es

>> Ensayos

Hospital Clínic de Barcelona

Responsable U. Cancer: Maria Reig
Persona de contacto: Nuria Perez
Hospital: 932279803
nperezp@clinic.cat

>> Ensayos

Hospital Universitario Virgen de Valme

Responsable U. Cancer: Blanca Figueruela
Persona de Contacto: Lourdes Grande Santamaría
Hospital: 955015761
lgrandes@gmail.com

>> Ensayos

Complejo Hospitalario Universitario de Toledo

Responsable U. Cancer: Rafael Gómez Rodríguez
Persona de Contacto: Marta Romero Gutiérrez
Teléfono: 646443644
m.romero.gutierrez@gmail.com

>> Ensayos

Hospital Universitario de Canarias

Responsable U. Cancer: DALIA ELENA MORALES ARRAEZ
Hospital: 922678000
daliafma@gmail.com

>> Ensayos

Complejo Asistencial Universitario de León

Responsable U. Cancer: Francisco Jorquera Plaza
Persona de contacto: Begoña Álvarez Cuenllas
Teléfono:680244672
bealvcue@gmail.com

>> Ensayos

Hospital Clínico Universitario de Santiago

Responsable U. Cancer: Javier Fernández Castroagudín
Teléfono: 619420992
javier.fernandez.castroagudin@sergas.es

>> Ensayos

Hospital Universitario Basurto

Responsable U. Cancer: Fernando Menéndez Blázquez
Persona de contacto: Sonia Blanco Sampascual
Hospital:944006000
sonia.blancosampascual@osakidetza.eus

>> Ensayos

Hospital Universitario Marqués de Valdecilla

Responsable U. Cancer: Carlos Rodríguez de Lope
Teléfono: 650902018
carlos.rodriguezdelope@scsalud.es

>> Ensayos

Hospital del Mar

Responsable U. Cancer: Susana Coll Estrada
Persona de contacto: Susana Coll y Marc Puigvehí
Hospital:932483217
scoll@parcdesalutmar.cat
mpuigvehi@parcdesalutmar.cat

>> Ensayos

Hospital Universitario de Badajoz

Responsable U. Cancer: J. Ignacio Delgado Mingorance
Persona de contacto: Ana Guiberteau Sánchez
Hospital:924218047
anaguisan@hotmail.com

>> Ensayos

Hospìtal Universitario de Getafe

Responsable U. Cancer: Mariano Gómez Rubio
Hospital:916834501
mgomezrubio@salud.madrid.org

>> Ensayos

Hospital Universitario Miguel Servet

Responsable U. Cancer: Javier Fuentes Olmo
Hospital:976765627
fuentesolmo@gmail.com

>> Ensayos

Hospital General de Segovia

Responsable U. Cancer: Marta Calvo Sanchez
Hospital:921419100
mcalvosan@saludcastillayleon.es

>> Ensayos

Hospital Josep Trueta Girona

Responsable U. Cancer: Margarita Sala Llinàs
Hospital: 972940200 Ext 2260
msalal.gorona.ics@gencat.cat

>> Ensayos

Consorci Sanitari de Terrassa

Responsable U. Cancer: Mercè Roget
Hospital:937839488
mroget@cst.cat

>> Ensayos

Clinica Universidad de Navarra

Responsable U. Cancer: Bruno Sangro Gomez-Acebo
Persona de contacto: Amaya Redin Garcia
Hospital: 948255400 (ext 4750)
areding@unav.es

>> Ensayos

Hospital Álvaro Cunqueiro

Responsable U. Cancer: Pamela Estévez
Persona de contacto: José Antonio Hermo
Hospital:986811111
Jose.Antonio.Hermo.Brion@sergas.es

>> Ensayos

 

Hospital Universitario de Fuenlabrada

Responsable U. Cancer: Maria Paz Valer López-Fando
Hospital: 916006302
mariapaz.valer@salud.madrid.org

>> Ensayos

Hospital Virgen de La Luz

Responsable U. Cancer: MARIA JULIA MORILLAS ARIÑO
Hospital: 969179928
mmorillas@sescam.jccm.es

Hospital Universitario Ramón y Cajal

Responsable U. Cancer: José Luis Lledó Navarro
jllledo63@yahoo.es

>> Ensayos

Hospital Universitario La Coruña

Responsable U. Cancer: Manuel Delgado Blanco
Hospital: 981178000
manuel.delgado.blanco@sergas.es

>> Ensayos

Hospital Universitario Donostia

Responsable U. Cancer: Juan I. Arenas Ruiz-Tapiador
Hospital: 943007173
juanignacio.arenasruiztapiador@osakidetza.eus

>> Ensayos

Hospital General Universitario de Valencia

Responsable U. Cancer: Juan José Urquijo Ponce
Hospital: 963131800
juanjo.urquijo@gmail.com

>> Ensayos

Hospital Universitario Central de Asturias

Responsable U. Cancer: María Varela Calvo
Persona de contacto: Ana Piedra Cerezal
Hospital: +34 985 108 000 EXT 72320
oncohep.gae4@sespa.es

>> Ensayos

Hospital Universitari Joan XXIII de Tarragona

Responsable U. Cancer: Silvia Montoliu
smontoliu.hj23.ics@gencat.cat

>> Ensayos

Hospital Universitario de Cáceres

Responsable U. Cancer: Miguel Fernández Bermejo
Teléfono hospital: 927256200 (Ext. 56024)
mfbermejo@gmail.com

>> Ensayos

Hospital Montecelo

Responsable U. Cancer: José Mera Calviño
Hospital:986800083
jose.manuel.mera.calvino@sergas.es

>> Ensayos

CIEMAT

Responsable U. Cancer: OSCAR QUINTANA
Hospital:913466000

>> Ensayos

Hospital Universitario La Paz

Responsable U. Cancer: Araceli García Sánchez
Hospital: 917277000
araceg1@gmail.com

>> Ensayos

Mapa de centros de referencia con ensayos clínicos abiertos para poder derivar pacientes desde otros hospitales.

Encuesta nov/2020

Resultados de la encuesta realizada en nov/2020 con la descripción de la actividad asistencial de los Centros Oncoliver

Publicaciones de los Centros Oncoliver

Publicaciones realizadas por los hepatólogos de la AEEH en el campo del cáncer hepático

publicaciones 2015-2021

Guías de práctica clínica

Guías de práctica clínica

V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante. Pardo F, Pons JA, Briceño J; en nombre de la Sociedad Española de Trasplante Hepático. Gastroenterol Hepatol.2015 Dec;38(10):600-18. doi: 10.1016/j.gastrohep.2015.06.008.

Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. Med Clin (Barc.) 2016;146:511.e1-511.e22

Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel. Samim M, van Veenendaal LM, Braat MNGJA, van den Hoven AF, Van Hillegersberg R, Sangro B, Kao YH, Liu D, Louie JD, Sze DY, Rose SC, Brown DB, Ahmadzadehfar H, Kim E, van den Bosch MAAJ, Lam MGEH. Eur Radiol. 2017 Dec; 27(12):4923-4930. doi: 10.1007/s00330-017-4889-6.

Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. Kennedy A, Brown DB, Feilchenfeldt J, Marshall J, Wasan H, Fakih M, Gibbs P, Knuth A, Sangro B, Soulen MC, Pittari G, Sharma RA. J Gastrointest Oncol. 2017 Dec;8(6):1079-1099. doi: 10.21037/jgo.2017.09.10.

Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. Aranda E, Aparicio J, Bilbao JI, García-Alfonso P, Maurel J, Rodríguez J, Sangro B, Vieitez JM, FeliuJ.FutureOncol. 2017 Oct; 13(23):2065-2082. doi: 10.2217/fon-2017-0220.

Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review. Sangro B, Martínez-Urbistondo D, Bester L, Bilbao JI, Coldwell DM, Flamen P, Kennedy A, Ricke J, Sharma RA. Hepatology. 2017 Sep;66(3):969-982. doi: 10.1002/hep.29207.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E; ESMO Guidelines Committee. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255. doi: 10.1093/annonc/mdy308.

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Ann Oncol. 2019 May 1;30(5):871-873. doi: 10.1093/annonc/mdy510.

Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, Bhoori S, Kwan Man N, Mas V, Ohira M, Sangro B, van der Laan LJW. Transplantation. 2020 Jun;104(6):1143-1149. doi: 10.1097/TP.0000000000003196.

Diagnóstico y tratamiento del carcinoma hepatocelular. Actualización del documento de consenso de la AEEH, AEC, SEOM, SERAM, SERVEI y SETH. María Reig, Alejandro Forner, Matías A. Ávila, Carmen Ayuso, Beatriz Mínguez, María Varela, Itxarone Bilbao, José Ignacio Bilbao, Marta Burrel, Javier Bustamante, Joana Ferrer, Miguel Ángel Gómez, Josep María Llovet, Manuel De la Mata, Ana Matilla, Fernando Pardo, Miguel A. Pastrana, Manuel Rodríguez-Perálvarez, Josep Tabernero, José Urbano, Ruth Vera, Bruno Sangro y Jordi Bruix. 10.1016/j.medcli.2020.09.022
International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Levillain H, Bagni O, Deroose CM, Dieudonné A, Gnesin S, Grosser OS, Kappadath SC, Kennedy A, Kokabi N, Liu DM, Madoff DC, Mahvash A, Martinez de la Cuesta A, Ng DCE, Paprottka PM, Pettinato C, Rodríguez-Fraile M, Salem R, Sangro B, Strigari L, Sze DY, de Wit van der Veen BJ, Flamen P. Eur J Nucl Med Mol Imaging. [12 enero 2021]

Originales

ORIGINALES

Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis. Ferrín G, Rodríguez-Perálvarez M, Aguilar-Melero P, Ranchal I, Llamoza C, Linares CI, González-Rubio S, Muntané J, Briceño J, López-Cillero P, Montero-Álvarez JL, de la Mata M.PLoSOne. 2015 Mar 19;10(3):e0118527. doi: 10.1371/journal.pone.0118527.

Tratamiento percutáneo del carcinoma hepatocelular en pacientes con edad avanzada en la práctica clínica.Romero Gutiérrez M, Ruano Díaz L, Muñoz López D, ArtazaVarasa T, González de Frutos C, Sánchez Ruano JJ, de la Cruz Pérez G, Gómez Rodríguez R.GastroenterolHepatol. 2015 Feb; 38(2):54-61. doi: 10.1016/j.gastrohep.2014.11.002.

Sensitivity to anti-Fas is independent of increased cathepsin D activity and adrenodoxin reductase expression occurring in NOS-3 overexpressing HepG2 cells. Linares CI, Ferrín G, Aguilar-Melero P, González-Rubio S, Rodríguez-Perálvarez M, Sánchez-Aragó M, Chicano-Gálvez E, Cuezva JM, Montero-Álvarez JL, Muntané J, de la Mata M.BiochimBiophys Acta. 2015May;1853(5):1182-94. doi: 10.1016/j.bbamcr.2015.02.015.

Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.Ciria R, López-Cillero P, Gallardo AB, Cabrera J, Pleguezuelo M, Ayllón MD, Luque A, Zurera L, Espejo JJ, Rodríguez-Perálvarez M, Montero JL, de la Mata M, Briceño J.Eur J SurgOncol. 2015 Sep;41(9):1153-61. doi: 10.1016/j.ejso.2015.05.023.

Histologic study of the effects of chemoembolization with preloaded  doxorubicin beads in patients with hepatocellular carcinoma. Zurera LJ, Espejo JJ, Lombardo S, Marchal T, Muñoz MC, Canis M, Montero JL. Radiologia. 2015 Sep-Oct;57(5):419-27. doi: 10.1016/j.rx.2014.07.008.

Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España [Therapeuticdecisions in thetreatment of hepatocellular carcinoma and patterns of sorafenib use. Results of theinternationalobservational GIDEON trial in Spain]. Turnes J, Díaz R, Hernandez-Guerra M, Gómez M, Castells L, Bustamante J, Espinosa MD, Fernández-Castroagudín J, Serrano T, Rendón P, Andrade R, Salgado M, Arenas J, Vergara M, Sala M, Polo BA, Granizo IM, Gonzálvez ML, Viudez A. GastroenterolHepatol. 2015;38(4):263-73. Spanish.

Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis. Ferrín G, Rodríguez-Perálvarez M, Aguilar-Melero P, Ranchal I, Llamoza C, Linares CI, González-Rubio S, Muntané J, Briceño J, López-Cillero P, Montero-Álvarez JL, de la Mata M.PLoSOne. 2015 Mar 19;10(3):e0118527. doi: 10.1371/journal.pone.0118527.

Sensitivity to anti-Fas is independent of increased cathepsin D activity and adrenodoxin reductase expression occurring in NOS-3 overexpressing HepG2 cells. Linares CI, Ferrín G, Aguilar-Melero P, González-Rubio S, Rodríguez-Perálvarez M, Sánchez-Aragó M, Chicano-Gálvez E, Cuezva JM, Montero-Álvarez JL, Muntané J, de la Mata M.BiochimBiophys Acta. 2015May;1853(5):1182-94. doi: 10.1016/j.bbamcr.2015.02.015.

Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.Ciria R, López-Cillero P, Gallardo AB, Cabrera J, Pleguezuelo M, Ayllón MD, Luque A, Zurera L, Espejo JJ, Rodríguez-Perálvarez M, Montero JL, de la Mata M, Briceño J.Eur J SurgOncol. 2015 Sep;41(9):1153-61. doi: 10.1016/j.ejso.2015.05.023.

Histologic study of the effects of chemoembolization with preloaded  doxorubicin beads in patients with hepatocellular carcinoma. Zurera LJ, Espejo JJ, Lombardo S, Marchal T, Muñoz MC, Canis M, Montero JL. Radiologia. 2015 Sep-Oct;57(5):419-27. doi: 10.1016/j.rx.2014.07.008.

Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundación Alcorcón. LoinazSegurola C, Lledó Navarro JL, De La Cruz Burgos R, Martín Rios D, Ochando Cerdán F, Alonso López S, Martel Villagrán J, Gutiérrez García ML, Fernández Cebrian JM, Fernández Rodríguez C. Hepatogastroenterology2015; 62: 971- 977.

Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. Hernández-Guerra M, Hernández-Camba A, Turnes J, Ramos LM, Arranz L, Mera J, Crespo J, Quintero E. UnitedEuropeanGastroenterol J. 2015;3(3):284-93.

Transarterial chemoembolisation in intermediate-stage hepatocellular carcinoma. Survey on clinical practice in hospitals in the Madrid Region. Matilla Peña A, Núñez Martínez O, Díaz Sánchez A, Pons Renedo F, Gómez Rubio M,  Polo Lorduy B, Lledó Navarro JL, Trapero Marugán M, Ladero Quesada JM, Poves Martínez E, Ibañez Pinto A, Martín Algivez AM, Lozano Maya M, González Alonso R, Piqueras Alcol B, González Moreno L, Fernández Rodríguez C, Gea Rodríguez F. Annals of Hepatology 2015; 14 (2): 207-217.

Unique genomic profile of fibrolamellar hepatocellular carcinoma. Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesús M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM. Gastroenterology. 2015;148(4):806-18.e10.

Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Kolligs FT, Bilbao JI, Jakobs T, Iñarrairaegui M, Nagel JM, Rodriguez M, Haug A, D’Avola D, op den Winkel M, Martinez-Cuesta A, Trumm C, Benito A, Tatsch K, Zech CJ, Hoffmann RT, Sangro B. Liver International. 2015; 35: 1715-1721.

Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules < 2 cm. Forner A, Vilana R, Bianchi L, Rodríguez-Lope C, Reig M, García-Criado MA, Rimola J, Solé M, Ayuso C, Bru C, Bruix J. J. Hepatol2015;62(1):150-155

SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, Bruix J, Qin S, Thuluvath PJ, Llovet JM, Leberre MA, Jensen M, Meinhardt G, Kang YK. J Clin Oncol.2015;33(6):559-566

Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience.  de la Serna S, Vilana R, Sánchez-Cabús S, Calatayud D, Ferrer J, Molina V, Fondevila C, Bruix J, Fuster J, García-Valdecasas JC. HPB (Oxford). 2015;17:387-393

Liver imaging reporting and data system with MR Imaging: Evaluation in nodules 20 mm or smaller detected in cirrhosis at screening US. Darnell A, Forner A, Rimola J, Reig M, García-Criado Á, Ayuso C, Bruix J. Radiology 2015;275:698-707

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Berre ML, Meinhardt G, Llovet JM; STORM investigators. Lancet Oncol 2015;16:1344-54

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O’Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. J Clin Oncol. 2015 Feb 20;33(6):550-8. doi: 10.1200/JCO.2014.57.9151.

Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK. Pennington B, Akehurst R, Wasan H, Sangro B, Kennedy AS, Sennfält K, Bester L. J Med Econ. 2015;18(10):797-804. doi: 10.3111/13696998.2015.1047779.

Assessment of the Hong Kong Liver Cancer Staging System in Europe. Kolly P, Reeves H, Sangro B, Knöpfli M, Candinas D, Dufour JF. Liver Int. 2016 Jun;36(6):911-7. doi: 10.1111/liv.13045.

AP-1 Inhibition by SR 11302 Protects Human Hepatoma HepG2 Cells from Bile Acid-Induced Cytotoxicity by Restoring the NOS-3 Expression. González-Rubio S, Linares CI, Aguilar-Melero P, Rodríguez-Perálvarez M, Montero-Álvarez JL, de la Mata M, Ferrín G.PLoSOne. 2016Aug 4;11(8):e0160525. doi: 10.1371/journal.pone.0160525.

Liver Cancer Arterial Perfusion Modelling and CFD Boundary Conditions Methodology: A Case Study of the Haemodynamics of a Patient-Specific Hepatic Artery in Literature-Based Healthy and Tumour-Bearing Liver Scenarios. Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI. Int J Numer Method Biomed Eng. 2016 Nov;32(11). doi: 10.1002/cnm.2764.

Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. Toyoda H, Lai PB, O’Beirne J, Chong CC, Berhane S, Reeves H, Manas D, Fox RP, Yeo W, Mo F, Chan AW, Tada T, Iñarrairaegui M, Vogel A, Schweitzer N, Chan SL, Sangro B, Kumada T, Johnson PJ.Br J Cancer. 2016 Mar 29;114(7):744-50. doi: 10.1038/bjc.2016.33.

Numerical investigation of liver radioembolization via computational particle-hemodynamics: The role of the microcatheter distal direction and microsphere injection point and velocity. Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI. J Biomech. 2016 Nov 7;49(15):3714-3721. doi: 10.1016/j.jbiomech.2016.09.034.

Computational assessment of the effects of the catheter type on particle-hemodynamics during liver radioembolization. Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI. J Biomech. 2016 Nov 7;49(15):3705-3713. doi: 10.1016/j.jbiomech.2016.09.035.

The  use of β-blockers is associated with a lower risk of developing hepatocellular  carcinoma in patients with cirrhosis. Herrera I, Pascual S, Zapater P, Carnicer F, Bellot P, María Palazón J. Eur J Gastroenterol Hepatol. 2016; 28(10):1194-7.

Akt-mediated Fox01 inhibition is required for liver regeneration. Pauta M, Rotllan N, Fernández-Hernando A, Langhi C, Ribera J, Lu M, Boix L, Bruix J, Jiménez W, Suárez Y, Ford DA, Baldán A, Birnbaum MJ, Morales-Ruiz M, Fernández-Hernando C. Hepatology 2016;63:1660-1674

Sorafenib or Placebo plus TACE with Doxorubicin-Eluting Beads for Intermediate-Stage HCC: Phase II, Randomized, Double-Blind SPACE Trial. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, Luca A, Del Arbol LR, Leberre MA, Niu W, Nicholson K, Meinhardt G, Bruix J. Hepatology 2016:64:1090-1098.

Prospective validation of “ab initio” liver transplantation in hepatocellular carcinoma upon detection of risk factors for recurrence after resection. Ferrer-Fàbrega J, Forner A, Liccioni A,Miquel R, Molina V, Navasa M, Fondevila C, García-Valdecasas JC, Bruix J, Fuster J. Hepatology Hepatology2016; 63:839-849.

Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, Díaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X, Bruix J. J Hepatol. 2016;65:719-726

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. Abou-Alfa GK, Puig O, Daniele B, Kudo M, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryoo BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyj S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ. J Hepatol. 2016;65(2):289-95.

Liver transplantation for “very early” intrahepatic cholangiocarcinoma. international retrospective study supporting a prospective assessment. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao F, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale C, Cucchetti A, Pinna A, Hwang S, Lee S, Agopian V, Busuttil R, Rizvi S, Heimbach J, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Tw Kim P, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J; iCCAInternational Consortium. Hepatology. 2016;64:1178-1188

A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.  de la Torre MA, Buades-Mateu J, de la Rosa PA, Lué A, Bustamante FJ, Serrano MT, Testillano M, Lorente S, Arenas JI, Gil C, Iñarrairaegui M, Sangro B.  Liver Int. 2016; 36(8):1206-12.

Restoring mir122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through smad-independent TGF-β pathway. Boix L, López-Oliva JM, Rhodes AC, Bruix J. Oncotarget. 2016;7(44):71309-71329

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Lancet 2017;389(10064):56-66

Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers. C Rodriguez de Lope, M Reig, A Matilla, MT Ferrer, E Dueñas, B Mínguez, J Castroagudín, I Ortiz, S Pascual,  JL Lledó, A Gallego, JI Arenas, C Aracil, M Fome, C Muñoz, F Pons, M Sala, M Iñarrairaegui, M Martin-Llahi, V Andreu, C Garre, P Rendón, J Fuentes, J Crespo, M Rodríguez, J Bruix, M Varela, en representación del Grupo de Estudio de Cáncer Hepático (GECH). Med. Clin. (Barc) 2017;149(2):61-71

Adherence to a semiannual surveillance program for hepatocellular carcinoma in patients with liver cirrhosis. Mancebo A, González-Diéguez ML, Navascués CA, Cadahía V, Varela M, Pérez R, Rodrigo L, Rodríguez M.J ClinGastroenterol. 2017 Jul;51(6):557-563. doi: 10.1097/MCG.0000000000000734.

Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. Lué A, Serrano MT, Bustamante FJ, Iñarrairaegui M, Arenas JI, Testillano M, Lorente S, Gil C, de la Torre M, Gomez A, Sangro B.  Oncotarget. 2017; 8(61):103077-103086.

Prognostic factors and predictors of Sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Bruix, AL Cheng, G Meinhardt, K Nakajima, Y de Sanctis, J Llovet. J Hepatol 2017;67:999-1008.

Computational Particle-Hemodynamics Analysis of Liver Radioembolization Pretreatment as an Actual Treatment Surrogate. Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI.Int J Numer Method Biomed Eng. 2017 Feb;33(2). doi: 10.1002/cnm.2791.

Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Waked I, Berhane S, Toyoda H, Chan SL, Stern N, Palmer D, Tada T, Yeo W, Mo F, Bettinger D, Kirstein MM, Iñarrairaegui M, Gomaa A, Vogel A, Meyer T, Sangro B, Lai P, Kumada T, Johnson PJ. Br J Cancer. 2017 Feb 14;116(4):448-454. doi: 10.1038/bjc.2016.423.

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2.

The role of angled-tip microcatheter and microsphere injection velocity in liver radioembolization: a computational particle-hemodynamics study. Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI. Int J Numer Method Biomed Eng. 2017 Dec;33(12). doi: 10.1002/cnm.2895.

NatB-mediated protein N-α-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma. Neri L, Lasa M, Elosegui-Artola A, D’Avola D, Carte B, Gazquez C, Alve S, Roca-Cusachs P, Iñarrairaegui M, Herrero J, Prieto J, Sangro B, Aldabe R. Oncotarget. 2017 Jun 20;8(25):40967-40981. doi: 10.18632/oncotarget.17332.

Incidental hepatocellular carcinoma after liver transplantation: Prevalence, histopathological features and prognostic impact. Pérez P, Rodríguez-Perálvarez M, Guerrero L, González V, Sánchez R, Centeno M, Poyato A, Briceño J, Sánchez-Frías M, Montero JL, De la Mata M.PLoSOne. 2017Apr 12;12(4):e0175010. doi: 10.1371/journal.pone.0175010.

The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. Pardo F, Sangro B, Lee RC, Manas D, Jeyarajah R, Donckier V, Maleux G, Pinna AD, Bester L, Morris DL, Iannitti D, Chow PK, Stubbs R, Gow PJ, Masi G, Fisher KT, Lau WY, Kouladouros K, Katsanos G, Ercolani G, Rotellar F, Bilbao JI, Schoen M. Ann Surg Oncol. 2017 Sep;24(9):2465-2473. doi: 10.1245/s10434-017-5950-z.

Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation. González R, De la Rosa ÁJ, Rufini A, Rodríguez-Hernández MA, Navarro-Villarán E, Marchal T, Pereira S, De la Mata M, Müller-Schilling M, Pascasio-Acevedo JM, Ferrer-Ríos MT, Gómez-Bravo MA, Padillo FJ, Muntané J.PLoSOne. 2017 Mar 28;12(3):e0174326. doi: 10.1371/journal.pone.0174326.

Is a Technetium-99m Macroaggregated Albumin Scan Essential in the Workup for Selective Internal Radiation Therapy with Yttrium-90? An Analysis of 532 Patients. Sancho L, Rodriguez-Fraile M, Bilbao JI, BeorleguiArteta C, Iñarrairaegui M, Moran V, Sangro B. J VascIntervRadiol. 2017 Nov;28(11):1536-1542. doi: 10.1016/j.jvir.2017.07.019.

The ART-SCORE is not an effective tool for  optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish  study. Pipa-Muñiz M, Castells L, Pascual S, Fernández-Castroagudín J, Díez-Miranda  I, Irurzun J, Díaz-Beveridge R, Senosiaín M, Arenas J, de la Mata M, Turnes J,  Monge-Romero MI, Pérez-Enguix D, Bustamante-Schneider J, Otegui N, Molina-Pérez  E, Rodríguez-Menéndez JE, Varela M. Gastroenterol Hepatol. 2017; 40(8):515-524.

Direct antiviral agents against hepatitis C virus: Beneficial or  harmful? Murcia Ó, Carnicer F, Gómez-Escolar L, Miralles C, Griñó MP, Barquero Martín C, Pascual S. J Hepatol. 2018;68(4):844-845.

Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Rodríguez-Perálvarez M, Guerrero M, Barrera L, Ferrín G, Álamo JM, Ayllón MD, Artacho GS, Montero JL, Briceño J, Bernal C, Padillo J, Marín-Gómez LM, Pascasio JM, Poyato A, Gómez-Bravo MA, De la Mata M.Transplantation. 2018 Dec;102(12):2056-2064. doi: 10.1097/TP.0000000000002270.

CD5L is upregulated in hepatocellular carcinoma and promotes liver cancer cell proliferation and antiapoptotic responses by binding to HSPA5 (GRP78).   Aran G, Sanjurjo L, Bárcena C, Simon-Coma M, Téllez É, Vázquez-Vitali M, Garrido M, Guerra L, Díaz E, Ojanguren I, Elortza F, Planas R, Sala M, Armengol C, Sarrias MR. FASEB J. 2018;32(7):3878-3891.

Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Llerena S, García-Díaz N, Curiel-Olmo S, Agraz-Doblas A, García-Blanco A, Pisonero H, Varela M, Santibáñez M, Almaraz C, Cereceda L, Martínez N, Arias-Loste MT, Puente Á, Martín-Ramos L, de Lope CR, Castillo-Suescun F, Cagigas-Fernandez C, Isidro P, Lopez-López C, Lopez-Hoyos M, Llorca J, Agüero J, Crespo-Facorro B, Varela I, Piris MÁ, Crespo J, Vaqué JP.Oncotarget. 2018 Jul 20;9(56):30869-30882. doi: 10.18632/oncotarget.25766.

Complete response under Sorafenib in patients with hepatocellular carcinoma. Relationshipwithdermatologic adverse events. J Rimola, A Díaz-González, A Darnell, M Varela, F Pons, M Hernández-Guerra, M Delgado, J Castroagudin, A Matilla, B Sangro, CR de Lope, M Sala, C González, C Huertas, B Mínguez, C Ayuso, J Bruix, M Reig. Hepatology 2017; Hepatology 2018;67:612-622

Incidence and risk factors associated with hepatocellular carcinoma surveillance failure. Mancebo A, Varela M, González-Diéguez ML, Navascués CA, Cadahía V, Mesa-Álvarez A, Rodrigo L, Rodríguez M.J GastroenterolHepatol. 2018 Aug;33(8):1524-1529. doi: 10.1111/jgh.14108.

Analysis of  survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug eluting  bead transarterial chemoembolization. Sánchez-Delgado J, Vergara M, Machlab S, Lira A, Gómez Zaragoza C, Criado E, Rosinach M, Batista L,  Arau B, Roget M, Ortiz J, Garcia C, Sort P, Casas M, Dalmau B, Forné M, Falcó J, Miquel M. Eur J GastroenterolHepatol. 2018; 30(12):1453-1460.

Tivantinib for second-line treatment of MET-high advanced hepatocellular carcinoma (METIV-HCC): a phase 3, randomised, placebo-controlled study. L Rimassa, E Assenat, M Peck‑Radosavljevic, M Pracht, V Zagonel, P Mathurin, E Rota, C Porta, B Daniele, L Bolondi, V Mazzaferro, W Harris, N Damjanov, D Pastorelli, M Reig, J Knox, F Negri, J Trojan, C López, N Personeni, T Decaens, M Dupuy, W Sieghart, G Abbadessa, B Schwartz, M Lamar, T Goldberg, D Shuster, A Santoro, J Bruix. Lancet Oncology 2018;19(5):682-693.

Current allocation policy is favorable for patients with hepatocellular carcinoma waiting for liver transplantation.  Carlos Ferre, José Luis Lledó, Lara Aguilera, Ana Garcia de Paredes, Enrique Rodríguez de Santiago, Javier Graus, Miguel García González, Javier Nuño, Adolfo López Buenadicha, Pedro López Hervás, Miguel Rodríguez Gandía, Francisco Gea, Agustín Albillos.  Digestive and Liver Disease 2018;50(12):1345-1350.

The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. Pinato DJ, Sharma R, Citti C, Platt H, Ventura-Cots M, Allara E, Chen TY, Dalla Pria A, Jain M, Mínguez B, Kikuchi L, Kaufman West E, Merli M, Kaplan DE, Hasson H, Marks K, Nelson M, Núñez M, Aytaman A, Bower M, Bräu N; Liver Cancer in HIV Study Group.AlimentPharmacolTher. 2018;47(1):95-103.

Outcomes of sequential treatment with Sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, Bruix J. J Hepatol. 2018; 69(2):353-358.

Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. Sangro B, Maini CL, Ettorre GM, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Sciuto R, Pizzi G, Lastoria S; European Network on Radioembolization with Yttrium-90 resin microspheres (ENRY). Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1721-1730. doi: 10.1007/s00259-018-3968-5.

Numerical zero-dimensional hepatic artery hemodynamics model for balloon-occluded transarterial chemoembolization. Aramburu J, Antón R, Rivas A, Ramos JC, Larraona GS, Sangro B, Bilbao JI. Int J Numer Method Biomed Eng. 2018 Jul;34(7):e2983. doi: 10.1002/cnm.2983.

Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. CasadeiGardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, SangroB.Onco Targets Ther. 2018 Oct 25;11:7315-7321. doi: 10.2147/OTT.S175715.

A methodology for numerically analysing the hepatic artery haemodynamics during B-TACE: a proof of concept. Aramburu J, Antón R, Rivas A, Ramos JC, Larraona GS, Sangro B, Bilbao JI. Comput Methods Biomech Biomed Engin. 2019 Apr;22(5):518-532. doi: 10.1080/10255842.2019.1567720.

Identification of coding and long noncoding RNAs differentially expressed in tumors and preferentially expressed in healthy tissues. Unfried JP, Serrano G, Suárez B, Sangro P, Ferretti V, Prior C, Boix L, Bruix J, Sangro B, Segura V, Fortes P. Cancer Res. 2019 Oct 15;79(20):5167-5180. doi: 10.1158/0008-5472.CAN-19-0400.

Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. Cappelli A, Sangro P, Mosconi C, Deppe I, Terzi E, Bilbao JI, Rodriguez-Fraile M, De Benedittis C, Ricke J, Golfieri R, SangroB.Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):661-668. doi: 10.1007/s00259-018-4152-7.

Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis. Banales JM, Iñarrairaegui M, Arbelaiz A, Milkiewicz P, Muntané J, Muñoz-Bellvis L, La Casta A, Gonzalez LM, Arretxe E, Alonso C, Martínez-Arranz I, Lapitz A, Santos-Laso A, Avila MA, Martínez-Chantar ML, Bujanda L, Marin JJG, Sangro B, Macias RIR. Hepatology. 2019 Aug;70(2):547-562. doi: 10.1002/hep.30319.

Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, Lasarte JJ, Pivette P, Trochon-Joseph V, Vasseur B, Dixon G, Sangro B, Sarobe P. Cancer Immunol Immunother. 2019 Mar;68(3):379-393. doi: 10.1007/s00262-018-2283-0.

mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. Guerrero M, Ferrín G, Rodríguez-Perálvarez M, González-Rubio S, Sánchez-Frías M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllón MD, Barrera P, Montero JL, de la Mata M.Int J Mol Sci. 2019Jan 15;20(2):336. doi: 10.3390/ijms20020336.

Molecular predictions of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhang Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gane E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Solé M, Thung SN, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. Gut 2019;68(6):1065-1075

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M. Am J Transplant. 2019 Nov;19(11):3176-3184. doi: 10.1111/ajt.15551.

Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma. Teufel M, Seidel H, Köchert K, Meinhardt G, Finn RS, Llovet JM, Bruix J. Gastroenterology 2019;156(6)1731-1741

Time Association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules. Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodríguez M, de Lope CR, Llerena S, torras X, Gallego A, Sala M, Morillas RM, Mínguez B, Llaneras J, Coll S, Carrión JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M. J Hepatol 2019;70(5):874-884

Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma n newly detected nodules ≤2 cm in cirrhosis. Ayuso C, Forner A, Darnell A, Rimola J, García-Criado Á, Bianchi L, Vilana R, Oliveira R, Llarch N, Bruix J. Liver Int. 2019 ; 39(7):1281-1291

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced  hepatocellular carcinoma. Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovič P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P. J Hepatol. 2019;71(6):1164-1174.

Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. Pinato DJ, Allara E, Chen TY, Trevisani F, Minguez B, Zoli M, Harris M, Dalla Pria A, Merchante N, Platt H, Jain M, Caturelli E, Kikuchi L, Pineda J, Nelson M, Farinati F, Rapaccini GL, Aytaman A, Yin M, Tan CK, Bower M, Giannini EG, Bräu N; Liver Cancer in HIV and ITA.LI.CA Study Groups.J Clin Oncol. 2019;37(4):296-304.

Characteristics and survival of hepatocelular carcinoma in non-cirrhotic liver. Romero-Gutiérrez M, Abanades Tercero M, Ruiz Martín J, Castro Limo JD, ArtazaVarasa T, González de Frutos C, de la Cruz Pérez G, Sánchez Ruano JJ, Gómez Moreno AZ, Gómez Rodríguez R.RevEspEnfermDig. 2019Oct;111(10):760-766. doi: 10.17235/reed.2019.6180/2018.

International and multicenter real-world study of Sorafenib-treated patients with hepatocellular carcinoma under dialysis. Díaz-González Á, Sanduzzi-Zamparelli M, da Fonseca LG, Di Costanzo GG, Alves R, Iavarone M, Leal C, Sacco R, Matilla AM, Hernández-Guerra M, AballaySoteras G, Wörns MA, Pinter M, Varela M, Ladekarl M, Chagas AL, Mínguez B, Arenas JI, Granito A, Sánchez-Torrijos Y, Rojas Á, Rodríguez de Lope C, Alvares-da-Silva MR, Pascual S, Rimassa L, Lledó JL, Huertas C, Sangro B, Giannini EG, Delgado M, Vergara M, Perelló C, Lue A, Sala M, Gallego A, Coll S, Hernáez T, Piñero F, Pereira G, França A, Marín J, Anders M, Mello V, Lozano M, Nault JC, Menéndez J, García Juárez I, Bruix J, Reig M. Liver Int. 2020; 40(6):1467-1476.

Regorafenib alteration of the BCL-xL/MCL-1 Ratio provides a therapeutic opportunity for BH3-Mimetics in heatocellular carcinoma models. Cucarull B, Tutusaus A, Subías M, Stefanovic M, Hernáez-Alsina T, Boix L, Reig M, García de Frutos P, Marí M, Colell A, Bruix J, Morales A. Cancers (Basel). 2020; 1;12(2) 80.

Bespoken nanoceria: a new effective treatment in experimental hepatocellular carcinoma. Fernández-Varo G, Perramón M, Carvajal S, Oró D, Casals E, Boix L, Oller L, Macías-Muñoz L, Marfà S, Casals G, Morales-Ruiz M, Casado P, Cutillas PR, Bruix J, Navasa M, Fuster J, Garcia-Valdecasas JC, Pavel MC, Puntes V, Jiménez W. Hepatology. 2020; 72(4):1267-1282.

Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. Rimola J, Forner A, Sapena V, Llarch N, Darnell A, Díaz A, García-Criado A, Bianchi L, Vilana R, Díaz-González Á, Ayuso C, Bruix J, Reig M. EurRadiol. 2020; 30(1):186-194.

Impact of HIV on the survival of hepatocellular carcinoma in hepatitis C virus-infected patients. Merchante N, Rodríguez-Fernández M, Figueruela B, Rodríguez-Arrondo F, Revollo B, Ibarra S, Téllez F, Merino E, Montero-Alonso M, Galindo MJ, Rivero-Juárez A, Santos IL, Delgado-Fernández M, García-Deltoro M, Vera-Méndez. AIDS 2020, Vol 34 No 10

On the importance of spiral-flow inflow boundary conditions when using idealized artery geometries in the analysis of liver radioembolization: A parametric study. Ortega J, Antón R, Ramos JC, Rivas A, Larraona GS, Sangro B, Bilbao JI, Aramburu J.Int J NumerMethodBiomedEng. 2020Jun;36(6):e3337. doi: 10.1002/cnm.3337.

Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study. Helmberger T, Arnold D, Bilbao JI, de Jong N, Maleux G, Nordlund A, Peynircioglu B, Sangro B, Sharma RA, Walk A.JMIR Res Protoc. 2020 Apr 22;9(4):e16296. doi: 10.2196/16296.

Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. Rimola J, Da Fonseca LG, Sapena V, Perelló C, Guerrero A, Simó MT, Pons M, De La Torre-Aláez M, Márquez L, Calleja JL, Lledó JL, Varela M, Mínguez B, Sangro B, Matilla A, Torres F, Ayuso C, Bruix J, Reig M.Eur J Radiol. 2020Dec 17;135:109484. doi: 10.1016/j.ejrad.2020.109484.

Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.  Díaz-González Á, Sapena V, Boix L, Brunet M, Torres F, LLarch N, Samper E, Millán O, Corominas J, Iserte G, Sanduzzi-Zamparelli M, da Fonseca LG, Darnell A, Belmonte E, Forner A, Ayuso C, Bruix J, Reig M.  Liver Int. 2020;40(10):2476-2488. doi: 10.1111/liv.14587. Epub 2020 Jul 25

Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial).Riaño I, Martín L, Varela M, Serrano T, Núñez O, Mínguez B, Rodrigues PM, Perugorria MJ, Banales JM, Arenas JI.Cancers (Basel). 2020;12(7):1900.

Immune-related hepatitis related to checkpoint inhibitors: Clinical and prognostic factors. Riveiro-Barciela M, Barreira-Díaz A, Vidal-González J, Muñoz-Couselo E, Martínez-Valle F, Viladomiu L, Mínguez B, Ortiz-Velez C, Castells L, Esteban R, Buti M. Liver Int. 2020; 40(8):1906-1916.doi: 10.1111/liv.14489.

Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabró R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J, Cabellos L, Maeda M, Villacorta-Martin C, Tabrizian P, Rodriguez-Carunchio L, Castellano G, Sempoux C, Minguez B, Pawlik TM, Labgaa I, Roberts LR, Sole M, Fiel MI, Thung S, Fuster J, Roayaie S, Villanueva A, Schwartz M, Llovet JM. J Hepatol. 2020;73(2):315-327.

Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. Pons M, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, Buti M, Augustin S, Forns X, Mínguez B, Genescà J. J Hepatol. 2020;72(3):472-480.

Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients. Díaz-González Á, Vilana R, Bianchi L, García-Criado Á, Rimola J, Rodríguez de Lope C, Ferrer J, Ayuso C, Da Fonseca LG, Reig M, Forner A J Vasc Interv Radiol. 2020; 31(5):710-719.

Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach. Urman JM, Herranz JM, Uriarte I, Rullán M, Oyón D, González B, Fernandez-Urién I, Carrascosa J, Bolado F, Zabalza L, Arechederra M, Alvarez-Sola G, Colyn L, Latasa MU, Puchades-Carrasco L, Pineda-Lucena A, Iraburu MJ, Iruarrizaga-Lejarreta M, Alonso C, Sangro B, Purroy A, Gil I, Carmona L, Cubero FJ, Martínez-Chantar ML, Banales JM, Romero MR, Macias RIR, Monte MJ, Marín JJG, Vila JJ, Corrales FJ, Berasain C, Fernández-Barrena MG, AvilaMA.Cancers (Basel). 2020 Jun 21;12(6):1644. doi: 10.3390/cancers12061644.

Efficacy and Safety  of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma  Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.  Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo  M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera  M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. JAMA Oncol. 2020 Oct 1:e204564.

Impact of Hepatic Artery Thrombosis on the Success of a Liver Transplant Because of Hepatocellular Carcinoma. Alconchel F, Martínez-Insfran LA, Cascales-Campos PA, Febrero B, Martínez-Alarcón L, Ríos A, Fernández-Hernández JA, Rodríguez JM, Ruiz-Merino G, Royo-Villanova M, Pons JA, Robles-Campos R, Sánchez-Bueno F, Ramírez P, Parrilla P.TransplantProc. 2020 Mar;52(2):559-561. doi: 10.1016/j.transproceed.2019.11.037.

Association of inflammatory biomarkers with clinical outcomes in nivolumab-  treated patients with advanced hepatocellular carcinoma. Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T,  Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A.   J Hepatol. 2020. 73(6):1460-1469.doi: 10.1016/j.jhep.2020.07.026.

The Pattern of Progression Defines Post-progression Survival in Patients with  Hepatocellular Carcinoma Treated with SIRT. de la Torre-Alvarez M, Jordán-Iborra C, Casadei-Gardini A, Bilbao JI,  Rodriguez-Fraile M, Sancho L, D’Avola D, Herrero JI, Iñarrairaegui M, Sangro B.  Cardiovasc InterventRadiol. 2020; 43(8):1165-1172.

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. Han G, Berhane S, Toyoda H, Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, García-Fiñana M, Gomaa A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ.Hepatology. 2020 Jul;72(1):198-212. doi: 10.1002/hep.31022.

Hepatic Flow Redistribution is Feasible in Patients with Hepatic Malignancies Undergoing Same-Day Work-Up Angiography and Yttrium-90 Microsphere Radioembolization.
Ezponda A, Rodríguez-Fraile M, Morales M, Vivas I, De La Torre M, Sangro B, Bilbao JI.CardiovascInterventRadiol. 2020Jul;43(7):987-995. doi: 10.1007/s00270-019-02371-x.

Short-term Safety and Quality of Life Outcomes Following  Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre  Analysis of 200 Patients in France. Loffroy R, Ronot M, Greget M, Bouvier A, Mastier C, Sengel C, Tselikas L,  Arnold D, Maleux G, Pelage JP, Pellerin O, Peynircioglu B, Sangro B, Schaefer N,  Urdániz M, Kaufmann N, Bilbao JI, Helmberger T, Vilgrain V; CIRT-FR Principal  Investigators. Cardiovasc InterventRadiol. 2021;44(1):36-49.doi: 10.1007/s00270-020-02643-x.

Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). Helmberger T, Golfieri R, Pech M, Pfammatter T, Arnold D, Cianni R, Maleux G, Munneke G, Pellerin O, Peynircioglu B, Sangro B, Schaefer N, de Jong N, Bilbao JI; On behalf of the CIRT Steering Committee; On behalf of the CIRT Principal Investigators.Cardiovasc Intervent Radiol. 2021 Jan;44(1):21-35. doi: 10.1007/s00270-020-02642-y.

Dual Pharmacological Targeting of HDACs and PDE5 Inhibits Liver Disease Progression in a Mouse Model of Biliary Inflammation and Fibrosis. Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, Sangro B, Rombouts K, Oyarzabal J, Marin JJG, Berasain C, Avila MA, Fernandez-Barrena MG. Cancers (Basel) [13-12-2020]

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. von Felden J, Craig AJ, Garcia-Lezana T, Labgaa I, Haber PK, D’Avola D, Asgharpour A, Dieterich D, Bonaccorso A, Torres-Martin M, Sia D, Sung MW, Tabrizian P, Schwartz M, Llovet JM, Villanueva A. Oncogene [enero-2021]

The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis. Pereira PL, Iezzi R, Manfredi R, Carchesio F, Bánsághi Z, Brountzos E, Spiliopoulos S, Echevarria-Uraga JJ, Gonçalves B, Inchingolo R, Nardella M, Pellerin O, Sousa M, Arnold D, de Baère T, Gomez F, Helmberger T, Maleux G.  Cardiovasc Intervent Radiol [enero-2021]

Assessment of the impact of COVID-19 pandemic on Liver Cancer Management (CERO-19), Sergio Muñoz-Martínez, Victor Sapena, Alejandro Forner et al. Journal of Hepatology Reports [enero-2021].

Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma. Juan L López-Cánovas, Mercedes Del Rio-Moreno, Helena García-Fernandez, Juan M Jiménez-Vacas, M Trinidad Moreno-Montilla, Marina E Sánchez-Frias, Víctor Amado, Fernando L-López, Marcos F Fondevila, Rubén Ciria et al. Cancer letters [enero 2021]

 

Revisiones

REVISIONES

Portal hypertension on the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Berzigotti A, Reig M, Abraldes JG, Bosch J, Bruix J. Hepatology 2015;(2):526-536.

Immunological landscape and immunotherapy of hepatocellular carcinoma. Prieto J, Melero I, Sangro B. Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):681-700. doi: 10.1038/nrgastro.2015.173.

Evidence-based diagnosis, staging and treatment of patients with hepatocellular carcinoma. Bruix J, Reig M, Sherman M. Gastroenterology 2016:150:835-853.43.

Carcinoma Hepatocelular.  J. Martínez, J.L. Lledó, M. Aicart-Ramos, B. Mateos, A. Albillos.  Medicine, 2016; 12 (12): 683-92.

New challenges in clinicalresearchonhepatocellular carcinoma. Díaz-González Á, Forner A, Rodríguez de Lope C, Varela M.RevEspEnfermDig. 2016 Aug;108(8):485-93. doi: 10.17235/reed.2015.4012/2015.

Hepatocellular carcinoma. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, GoresG.NatRevDisPrimers. 2016 Apr 14;2:16018. doi: 10.1038/nrdp.2016.18.

New advances in hepatocellular carcinoma. Pascual S, Herrera I, Irurzun J. World J Hepatol. 2016; 8(9):421-38

Targets for immunotherapy of liver cancer. Greten TF, Sangro B. J Hepatol. 2017 Sep 18:S0168-8278(17)32287-0. doi: 10.1016/j.jhep.2017.09.007.

Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. Iñarrairaegui M, Melero I, Sangro B. Clin Cancer Res. 2018 Apr 1;24(7):1518-1524. doi: 10.1158/1078-0432.CCR-17-0289.

Hepatocellular Carcinoma. A Forner, M Reig, Bruix J. Lancet. 2018;391(10127):1301-1314.

Hepatocellular carcinoma: Present and future. Armengol C, Sarrias MR, Sala M. Med Clin (Barc). 2018; 150(10):390-397.

The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Macias RIR, Banales JM, Sangro B, Muntané J, Avila MA, Lozano E, Perugorria MJ, Padillo FJ, Bujanda L, Marin JJG. BiochimBiophys Acta Mol Basis Dis. 2018 Apr; 1864(4 Pt B):1468-1477. doi: 10.1016/j.bbadis.2017.08.002.

Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Bruix J, da Fonseca LG, Reig M.   NatRevGastroenterolHepatol. 2019; 16(10):617-630

Medical treatmentforcholangiocarcinoma. Adeva J, Sangro B, Salati M, Edeline J, La Casta A, Bittoni A, Berardi R, Bruix J, Valle JW. Liver Int. 2019; Suppl1:123-142.

Surveillance and  diagnosis of hepatocellular carcinoma: A systematic review. Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. World J Clin Cases. 2019;7(16): 2269-2286.

Hepatocellular carcinoma: essentials interventional radiologists need to know. D’Avola D, Bilbao JI, Sangro B. Cardiovasc InterventRadiol. 2019 Sep;42(9):1262-1270. doi: 10.1007/s00270-019-02221-w.

Medical treatment for cholangiocarcinoma. Adeva J, Sangro B, Salati M, Edeline J, La Casta A, Bittoni A, Berardi R, Bruix J, Valle JW. Liver Int. 2019 May;39 Suppl 1:123-142. doi: 10.1111/liv.14100.

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with Sorafenib. Díaz-González A., Sanduzzi-Zamparelli M, Sapena V, Torres F, Llarch N, Insert G, Forner A, da Fonseca L, Rios J, Bruix J, Reig M. AlimentPharmacolTher. 2019;49(5):482-491

Cholangiocarcinoma 2020: the next horizon in mechanisms and management.  Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ.  Nat Rev Gastroenterol Hepatol. 2020;17(9):557-588. doi: 10.1038/s41575-020-0310-z.

Local and Regional Therapies for Hepatocellular Carcinoma.  Kloeckner R, Galle PR, Bruix J.  Hepatology. 2020 Jun 18. doi: 10.1002/hep.31424. Online ahead of print.

Diagnosis and  management of toxicities of immune checkpoint inhibitors in hepatocellular  carcinoma.  Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR. J Hepatol. 2020; 72(2): 320-341.

Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations. Delgado Martínez C, Gómez-Rubio M, Gómez-Domínguez C. Ann Hepatol. 2020 Jul 17;21:100225. doi: 10.1016/j.aohep.2020.05.007. Online ahead of print.

Liver radioembolization: an analysis of parameters that influence the catheter-based particle-delivery via CFD. Aramburu J, Antón R, Rivas A, Ramos JC, Sangro B, Bilbao JI.Curr Med Chem. 2020; 27(10):1600-1615. doi: 10.2174/0929867325666180622145647.

 

Editoriales

EDITORIALES

Radioembolization for hepatocellular carcinoma: gaining insight on a personalized approach. Sangro B, Rodriguez M. Liver Int. 2017 Jan;37(1):32-34. doi: 10.1111/liv.13300.

Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. Bruix J, Reig M, Sangro B.J Hepatol. 2017 Jun;66(6):1114-1117. doi: 10.1016/j.jhep.2017.02.032.

Oral oxycodone/naloxone for pain control in cirrhosis: Start slow, go slow. Varela M, Castaño-Garcia A.Liver Int. 2018 Feb;38(2):227-228. doi: 10.1111/liv.13605.

Milestones in the pathogenesis and management of primary liver cancer. Nault JC, Cheng AL, Sangro B, Llovet JM. J Hepatol. 2020 Feb;72(2):209-214. doi: 10.1016/j.jhep.2019.11.006.

Lymphocytes, Neutrophils and the Response to Selective Internal Radiation Therapy: More Questions than Answers Yet. de la Torre-Aláez M, Sangro B. Cardiovasc InterventRadiol. 2020Aug; 43(8):1182-1183. doi: 10.1007/s00270-020-02556-9.

 

Capítulos de libro

CAPÍTULOS DE LIBRO

Actualización en el proceso de donación y trasplantes 2018.  ISBN: 978-84-09-13134-1.  Capítulo de libro:   3.12. Trasplante hepático en hepatocarcinoma:  expansión de los criterios de Milán.   Lucena-Valera A.I., Giráldez-Gallego A., Carballo-Rubio V., Sousa-Martín J.M., Ferrer-Ríos M.T., Pascasio-Acevedo J.M.

The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Qadan M, Kothary N, Sangro B, Palta M. American Society of Clinical Oncology Educational Book 2020;40:1-8. DOI https://doi.org/10.1200/ EDBK_280811.

Casos Clínicos

CASOS CLINICOS

Orbital metástasis fromhepatocellular carcinoma. TellezVillajos L, Maroto Castellanos M, LledóNavarro JL, López Durán S, Moreira Vicente V, Albillos Martínez A. RevEspEnfermDig2015;  107 (4): 231.

Spontaneous regression of hepatocellular carcinoma. A case report.   Clos A, Hernández A, Sánchez MD, Tenesa M, Julián JF, Armengol C, Sala M. GastroenterolHepatol. 2017; 40(4):286-288.

Pneumatocele during sorafenib therapy: first report of an unusual complication. Sangro P, Bilbao I, Fernández-Ros N, Iñarrairaegui M, Zulueta J, Bilbao JI, Sangro B. Oncotarget. 2017 Dec 22;9(5):6652-6656. doi: 10.18632/oncotarget.23599.

Segmental Pneumonitis after Radioembolization. Jaureguizar JIB, Sancho L, Páramo M, Rodríguez-Fraile M, Chopitea A, Benito A, Iñarrairaegui M, Sangro B. J J Vasc Interv Radiol . 2018 Sep;29(9):1305-1306.doi: 10.1016/j.jvir.2018.04.010.

Oncoliver se actualiza cuatrimestralmente
Actualizado: Julio 2021
Contacto: webmaster@aeeh.es

fecha de actualización: 13/7/2021

Visit Us On FacebookVisit Us On TwitterVisit Us On YoutubeVisit Us On LinkedinVisit Us On Instagram
});